Skip to content
MPN Asia 2026
Welcome Program Faculty
MPN Asia 2026MPN Asia 2025MPN Asia 2024MPN Asia 2023MPN Asia 2019MPN Asia 2018MPN Asia 2017MPN Asia 2016
MPN Asia
WelcomeProgramFacultyGallery
MPN Asia 2026MPN Asia 2025MPN Asia 2024MPN Asia 2023MPN Asia 2019MPN Asia 2018MPN Asia 2017MPN Asia 2016

September 22, 2026

Therapeutic Advances & Clinical Trials in ET

September 22, 2026

Real-World Experience: Prospective Ropeginterferon Alfa-2b Therapy in PV & ET

September 22, 2026

Advancements in Essential Thrombocythemia Management

September 22, 2026

From Dosing Strategy to Clinical Benefit: Rethinking Interferon Use Patterns to Optimize Efficacy and Safety

September 22, 2026

BREAK

September 22, 2026

Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)

September 22, 2026

Metformin Alleviates Side Effects and Supports the Resumption of Interferon Therapy in PV and ET

September 22, 2026

Myeloproliferative Neoplasm Subtype Impacts Risk of Incident Osteoporosis and Osteoporotic Fractures

September 22, 2026

Panel Discussion

September 22, 2026

Closing Remarks

MPN Asia 2026

Conrad Seoul

10 Gukjegeumyung-ro, Yeongdeungpo District, Seoul, South Korea

+82 261377000

mpnasiaservice@gmail.com

© 2026 PharmaEssentia Corporation